MCID: ORL005
MIFTS: 50

Oral Candidiasis

Categories: Infectious diseases, Oral diseases

Aliases & Classifications for Oral Candidiasis

MalaCards integrated aliases for Oral Candidiasis:

Name: Oral Candidiasis 12 55 15 73
Thrush 12 76 3
Candidiasis of Mouth 12
Candidiasis, Oral 44
Oral Moniliasis 12
Equine Thrush 73
Thrush, Oral 12
Candidiasis 73
Oral Thrush 63

Classifications:



External Ids:

Disease Ontology 12 DOID:14262
ICD10 33 B37.0 B37.9
ICD9CM 35 112.0
MeSH 44 D002180
NCIt 50 C28137

Summaries for Oral Candidiasis

PubMed Health : 63 About oral thrush: Oral thrush is a condition that can be difficult to recognize at first. It is rarely dangerous and not necessarily painful, but can be very unpleasant and greatly affect your quality of life. Oral thrush is caused by types of yeast fungus called Candida that live in the mucous membranes lining your mouth. Its medical name “oral candidiasis” is taken from this fungus. Oral thrush is most often caused by a type of Candida fungus called Candida albicans.Most people have small amounts of Candida on the mucous linings of their mouth without it causing any noticeable problems. But given the right conditions, the fungus can start reproducing very quickly. This often affects people who have serious diseases, and it can also be a side effect of certain types of treatment.

MalaCards based summary : Oral Candidiasis, also known as thrush, is related to candidiasis and severe combined immunodeficiency, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is DEFB4A (Defensin Beta 4A), and among its related pathways/superpathways are Innate Immune System and Defensins. The drugs Fluticasone and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and kidney.

Disease Ontology : 12 A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives in the digestive tract and on skin without causing any problems.1 Sometimes, Candida can multiply and cause an infection if the environment inside the mouth, throat, or esophagus changes in a way that encourages fungal growth.

Wikipedia : 76 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Related Diseases for Oral Candidiasis

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 candidiasis 31.4 DEFB4A HTN3 SKAP2
2 severe combined immunodeficiency 11.0
3 jak3-deficient severe combined immunodeficiency 11.0
4 immunodeficiency 32b 11.0
5 reticular dysgenesis 11.0
6 median rhomboid glossitis 11.0
7 corneal abscess 10.7 DEFB1 DEFB4A
8 microsporidiosis 10.6 DEFA1 DEFB4A
9 osteonecrosis of the jaw 10.6 DEFB1 DEFB4A
10 vulvovaginal candidiasis 10.6 DEFB1 DEFB4A
11 dermatophytosis 10.6 DEFB4A LTF
12 pouchitis 10.5 CXCL8 LTF
13 vaginal disease 10.5 CXCL8 DEFB4A
14 giant papillary conjunctivitis 10.5 CXCL8 LTF
15 haemophilus influenzae 10.5 CXCL8 LTF
16 sinusitis 10.5 CXCL8 DEFB4A
17 periodontitis, aggressive, 1 10.4 IL1A LTF
18 septic arthritis 10.4 CXCL8 DEFB4A
19 leukoregulin 10.4 CXCL8 IL1A
20 scabies 10.4 CXCL8 IL1A
21 multidrug-resistant tuberculosis 10.3 DEFA1 IL1A
22 candida glabrata 10.3 HTN3 SKAP2
23 radiculopathy 10.2 CXCL8 IL1A
24 gastritis 10.2 CXCL8 DEFB1 DEFB4A
25 dysentery 10.2 IL1A LTF
26 leukoplakia 10.2
27 neurofibromatosis, type ii 10.2 DEFB1 DEFB4A IL1A
28 aseptic meningitis 10.2 CXCL8 IL1A
29 pulpitis 10.2 CXCL8 IL1A
30 mucositis 10.1
31 keratoconjunctivitis sicca 10.1 IL1A LTF
32 bullous keratopathy 10.1 CXCL8 IL1A
33 sebaceous gland disease 10.1 CXCL8 DEFB4A IL1A
34 bacterial vaginosis 10.1 CXCL8 DEFB4A IL1A
35 tibial neuropathy 10.1 B2M SKAP2
36 tarsal tunnel syndrome 10.0 B2M SKAP2
37 oral hairy leukoplakia 10.0
38 opportunistic mycosis 10.0 SKAP2 ST5
39 tonsillitis 10.0 CXCL8 DEFB1 IL1A
40 aggressive periodontitis 10.0 CXCL8 DEFB1 IL1A
41 vaginitis 10.0 CXCL8 DEFB4A SH2D1A
42 leukemia 10.0
43 acquired immunodeficiency syndrome 10.0
44 diabetes mellitus 9.9
45 acute leukemia 9.9
46 pleural tuberculosis 9.8 B2M CXCL8
47 asthma 9.8
48 pharyngitis 9.8
49 dermatitis 9.8
50 pneumonia 9.8

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 37)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease Anxiety
Bronchitis Bronchopneumonia
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Conn's Syndrome Decubitus Ulcer
Deficiency Anemia Dysthymic Disorder
Esophageal Candidiasis Esophagitis
Familial Atrial Fibrillation Glossitis
Heart Disease Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Ischemic Heart Disease Neutropenia
Osteoporosis Paralytic Ileus
Peripheral Vascular Disease Pharyngitis
Pneumocystosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Rheumatoid Arthritis Schizophreniform Disorder
Status Asthmaticus Swallowing Disorders
Vulvovaginal Candidiasis

Graphical network of the top 20 diseases related to Oral Candidiasis:



Diseases related to Oral Candidiasis

Symptoms & Phenotypes for Oral Candidiasis

UMLS symptoms related to Oral Candidiasis:


oral manifestations

Drugs & Therapeutics for Oral Candidiasis

PubMedHealth treatment related to Oral Candidiasis: 63

Oral thrush can be treated with antimycotics. These are available as drugs that produce either a topical (local) or a systemic (throughout the whole body) effect. Medication that acts in both ways is also an option. The type of medication that is best suited for someone with a weakened immune system will depend on their individual situation.

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 90566-53-3 62924
2
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
4
Zinc Approved, Investigational Phase 4 7440-66-6 23994
5 Adrenergic Agents Phase 4,Phase 3,Phase 2
6 Adrenergic Agonists Phase 4,Phase 3,Phase 2
7 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3,Phase 2
8 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
9 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
10 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Autonomic Agents Phase 4,Phase 3,Phase 2
13 Bronchodilator Agents Phase 4,Phase 3,Phase 2
14 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 3
16 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
18 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
22 Respiratory System Agents Phase 4,Phase 3,Phase 2
23
Salmeterol xinafoate Phase 4,Phase 3 94749-08-3 56801
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
27 Antifungal Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
29 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
30 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
31 Hypoglycemic Agents Phase 4
32 insulin Phase 4
33 Insulin, Globin Zinc Phase 4
34 Insulin, Isophane Phase 4
35 Insulin, Short-Acting Phase 4
36 Isophane insulin, beef Phase 4
37 Isophane Insulin, Human Phase 4
38 Antitubercular Agents Phase 4,Phase 3
39
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
40
Gentian Violet Approved Phase 3 7438-46-2, 14426-25-6 3468
41
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
42
Nystatin Approved, Vet_approved Phase 3,Phase 2,Not Applicable 1400-61-9 11953884
43
Pilocarpine Approved, Investigational Phase 3 54-71-7, 92-13-7 5910
44
Procaterol Approved, Investigational Phase 3 72332-33-3 688561
45
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
46
Budesonide Approved Phase 3 51333-22-3 63006 5281004
47
Ganciclovir Approved, Investigational Phase 2, Phase 3 82410-32-0 3454
48
Valganciclovir Approved, Investigational Phase 2, Phase 3 175865-60-8 64147
49
Sulfamethoxazole Approved Phase 3 723-46-6 5329
50
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
2 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
3 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
4 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
5 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
6 Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
7 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
8 Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Completed NCT00002446 Phase 3 Posaconazole;Fluconazole
9 A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
10 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Completed NCT01427738 Phase 3 Gentian Violet;Nystatin oral suspension
11 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic Completed NCT02818803 Phase 3 Miconazole
12 Effect of Probiotic Lozenge on Gingivitis and Periodontitis Completed NCT02203812 Phase 3 Probiotic Arm;Placebo Arm
13 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3 Salagen
14 Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Completed NCT02175771 Phase 3 Fp MDPI;FS MDPI;FLOVENT HFA;ADVAIR DISKUS;albuterol/salbutamol HFA
15 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
16 Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study Completed NCT01018186 Phase 3 Fluticasone Furoate/GW642444;Fluticasone propionate
17 Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy Completed NCT00152867 Phase 3 Dexamethasone
18 Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy Completed NCT02181335 Phase 3 Respimat® Budesonide low dose;Respimat® Budesonide high dose;Turbohaler® Budesonide;Placebo
19 A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
20 Prophylactic Antibiotics in Measles Completed NCT00168532 Phase 3 Sulfamethoxazole-Trimethoprim
21 A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma Completed NCT02040779 Phase 3 Beclomethasone dipropionate breath-actuated inhaler;Placebo breath-actuated inhaler;albuterol/salbutamol
22 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed NCT01941940 Phase 3 Tocilizumab;DMARDs
23 A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Recruiting NCT02635438 Phase 3 Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
24 Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Recruiting NCT03386539 Phase 3 Everolimus;Tacrolimus;Mycophenolate Mofetil
25 Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate Unknown status NCT01087476 Phase 2 Doxycycline hyclate
26 Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis Completed NCT00659971 Phase 2 PAC113
27 A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole Completed NCT00001065 Phase 2 Amphotericin B
28 Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches Completed NCT00835029 Phase 2 Clotrimazole varnish;Clotrimazole troches
29 Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin Completed NCT02525458 Phase 2
30 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications Completed NCT01576718 Phase 2 Fp MDPI;Flovent Diskus;albuterol/salbutamol
31 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
32 Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure Completed NCT00168116 Phase 2
33 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids Completed NCT01479621 Phase 2 Fp MDPI;Flovent Diskus;albuterol/salbutamol;Placebo MDPI
34 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy. Completed NCT00603746 Phase 2 GW685698X
35 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy. Completed NCT00603382 Phase 2 GW685698X;Placebo
36 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy. Completed NCT00603278 Phase 2 GW685698X;placebo
37 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis Recruiting NCT02315898 Phase 2 Treatment-inhaled tPA
38 CelAgace™ OraRinse Solution for Treatment of Candidiasis Enrolling by invitation NCT03250923 Phase 1, Phase 2 silver citrate complex and acemannan
39 Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole Terminated NCT00005920 Phase 2 L-743,872
40 Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas Terminated NCT00967226 Phase 2 propranolol;Prednisolone
41 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
42 The Effect of Palatal Brushing on Denture Stomatitis Completed NCT01643876 Phase 1
43 Sinovuyo Caring Families Project - Pilot Trial Completed NCT01802294 Phase 1
44 Modified Directly Observed Antiretroviral Therapy Unknown status NCT01985269 Not Applicable
45 Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy Completed NCT00768794 Not Applicable
46 Novel Rinse to Treat in Oral Candidiasis in Cancer Patients Completed NCT00612963 Frio Oral Rinse
47 Oral Candida in Infants and Dietary Type Completed NCT01438983
48 The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection Completed NCT00001448
49 Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC Completed NCT00002057 Not Applicable Nystatin
50 Effect of Probiotic Bacteria on Oral Candida in Frail Elderly Completed NCT02391532 Not Applicable

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: candidiasis, oral

Genetic Tests for Oral Candidiasis

Anatomical Context for Oral Candidiasis

MalaCards organs/tissues related to Oral Candidiasis:

41
Tongue, Skin, Kidney, Salivary Gland, Heart, Colon, Neutrophil

Publications for Oral Candidiasis

Articles related to Oral Candidiasis:

(show top 50) (show all 431)
# Title Authors Year
1
Th17 cells differentiated with mycelial membranes of Candida albicans prevent oral candidiasis. ( 29462298 )
2018
2
Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis. ( 29380647 )
2018
3
VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. ( 29788070 )
2018
4
Systemic hematogenous dissemination of mouse oral candidiasis is induced by oral mucositis. ( 29797142 )
2018
5
IL-36 and IL-1/IL-17 Drive Immunity to Oral Candidiasis via Parallel Mechanisms. ( 29891557 )
2018
6
Promising alternative therapeutics for oral candidiasis. ( 29852856 )
2018
7
Chair-Side Direct Microscopy Procedure for Diagnosis of Oral Candidiasis in an Adolescent. ( 29854484 )
2018
8
Prevalence and association of oral candidiasis with dysphagia in individuals with acquired brain injury. ( 29182379 )
2018
9
Amplitude-modulated cold atmospheric pressure plasma jet for treatment of oral candidiasis: In vivo study. ( 29949638 )
2018
10
Clinical and laboratorial features of oral candidiasis in HIV-positive patients. ( 29972567 )
2018
11
Dynamic changes of Th1/Th2/Th17 cytokines and human beta defensin 2 in HIV-infected patients with oral candidiasis during the first year of highly active anti-retroviral therapy. ( 29753928 )
2018
12
In Vivo Comparative Evaluation of the Pomegranate (Punica granatum) Peel Extract as an Alternative Agent to Nystatin against Oral Candidiasis. ( 29892147 )
2018
13
Quantity of Candida Colonies in Saliva: a8"A Diagnostic Evaluation for Oral Candidiasis. ( 28232964 )
2017
14
Development and Evaluation of Buccal Films Based on Chitosan for the Potential Treatment of Oral Candidiasis. ( 28108973 )
2017
15
Oral health: Asthma and oral candidiasis. ( 29123274 )
2017
16
TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients. ( 28403570 )
2017
17
Treatment and Prevention of Oral Candidiasis in Elderly Patients. ( 28566666 )
2017
18
Volatile organic compounds in the breath of oral candidiasis patients: a pilot study. ( 28601915 )
2017
19
The potential management of oral candidiasis using anti-biofilm therapies. ( 28818264 )
2017
20
Inherited IL-12RI^1 Deficiency in a Child With BCG Adenitis and Oral Candidiasis: A Case Report. ( 29025965 )
2017
21
Assessment of Effectiveness of Fluconazole and Clotrimazole in Treating Oral Candidiasis Patients: A Comparative Study. ( 28462176 )
2017
22
A meta-analysis of randomized trials assessing the effects of probiotic preparations on oral candidiasis in the elderly. ( 28783552 )
2017
23
Oral candidiasis: A retrospective study of 276 Brazilian patients. ( 29391707 )
2017
24
Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. ( 28748027 )
2017
25
Antifungal activity of linalool in cases of Candida spp. isolated from individuals with oral candidiasis. ( 28977047 )
2017
26
Elimination of oral candidiasis may increase stimulated whole salivary flow rate. ( 27497081 )
2016
27
Molecular analysis of fungal populations in patients with oral candidiasis using next-generation sequencing. ( 27305838 )
2016
28
Elucidating the Role of Hyposalivation and Autoimmunity in Oral Candidiasis. ( 27998016 )
2016
29
Adjuvant antifungal therapy using tissue tolerable plasma on oral mucosa and removable dentures in oral candidiasis patients: a randomised double-blinded split-mouth pilot study. ( 26932256 )
2016
30
Treatment of Oral Candidiasis Using PhotodithazineAr- Mediated Photodynamic Therapy In Vivo. ( 27253525 )
2016
31
Development and evaluation of N-naphthyl-N,O-succinyl chitosan micelles containing clotrimazole for oral candidiasis treatment. ( 27050629 )
2016
32
Plasma Levels of IFN-I^, IL-4, IL-6 and IL-17 in HIV-Positive Patients With Oral Candidiasis. ( 27127595 )
2016
33
The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial. ( 27977721 )
2016
34
FACTORS RELATED TO ORAL CANDIDIASIS IN ELDERLY USERS AND NON-USERS OF REMOVABLE DENTAL PROSTHESES. ( 27007560 )
2016
35
Oral candidiasis following steroid therapy for oral lichen planus. ( 26599999 )
2016
36
Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. ( 27042008 )
2016
37
Oral Candidiasis among Cancer Patients Attending a Tertiary Care Hospital in Chennai, South India: An Evaluation of Clinicomycological Association and Antifungal Susceptibility Pattern. ( 27403171 )
2016
38
Development, characterization, and in vivo assessment of mucoadhesive nanoparticles containing fluconazole for the local treatment of oral candidiasis. ( 27358561 )
2016
39
Prevention of Oral Candidiasis After Free Flap Surgery: Role of 3% Sodium Bicarbonate Saline in Oral Care. ( 27669373 )
2016
40
Quantification of oral palatine Langerhans cells in HIV/AIDS associated oral Kaposi sarcoma with and without oral candidiasis. ( 27461637 )
2016
41
Fluorescence of Candida in diagnosis of oral candidiasis. ( 28169259 )
2016
42
Oral candidiasis. ( 27343964 )
2016
43
Topical Antimycotics for Oral Candidiasis in Warfarin Users. ( 27901310 )
2016
44
Fabrication of mucoadhesive chitosan coated polyvinylpyrrolidone/cyclodextrin/clotrimazole sandwich patches for oral candidiasis. ( 26256338 )
2015
45
Direct Microscopy: A Useful Tool to Diagnose Oral Candidiasis in Children and Adolescents. ( 26329143 )
2015
46
C/EBPI^ Promotes Immunity to Oral Candidiasis through Regulation of I^-Defensins. ( 26317211 )
2015
47
In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. ( 26416861 )
2015
48
Novel aggregation properties of Candida albicans secreted aspartyl proteinase Sap6 mediates virulence in oral candidiasis. ( 25870228 )
2015
49
Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis. ( 26456226 )
2015
50
Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. ( 25819801 )
2015

Variations for Oral Candidiasis

Expression for Oral Candidiasis

Search GEO for disease gene expression data for Oral Candidiasis.

Pathways for Oral Candidiasis

Pathways related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 B2M CXCL8 DEFA1 DEFB1 DEFB4A HTN3
2
Show member pathways
11.38 DEFA1 DEFB1 DEFB4A HTN3 LTF
3 11.21 CXCL8 IL1A IRF8
4 10.95 CXCL8 IL1A

GO Terms for Oral Candidiasis

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 B2M CXCL8 DEFA1 DEFB1 DEFB4A IL1A
2 Golgi lumen GO:0005796 9.33 DEFA1 DEFB1 DEFB4A
3 extracellular region GO:0005576 9.23 B2M CXCL8 DEFA1 DEFB1 DEFB4A HTN3

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.78 CXCL8 DEFA1 DEFB1 DEFB4A
2 defense response GO:0006952 9.73 CXCL8 DEFA1 DEFB1 DEFB4A
3 cellular response to lipopolysaccharide GO:0071222 9.71 CXCL8 DEFA1 IRF8
4 immune response GO:0006955 9.7 B2M CXCL8 DEFA1 DEFB1 DEFB4A IL1A
5 defense response to Gram-positive bacterium GO:0050830 9.69 DEFA1 DEFB1 DEFB4A
6 defense response to Gram-negative bacterium GO:0050829 9.67 DEFA1 DEFB1 DEFB4A LTF
7 antibacterial humoral response GO:0019731 9.63 DEFA1 DEFB1 LTF
8 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.62 DEFA1 DEFB1 DEFB4A LTF
9 retina homeostasis GO:0001895 9.58 B2M LTF
10 iron ion homeostasis GO:0055072 9.58 B2M LTF
11 innate immune response in mucosa GO:0002227 9.58 DEFA1 DEFB1 LTF
12 response to bacterium GO:0009617 9.57 DEFB1 IRF8
13 defense response to fungus GO:0050832 9.56 DEFA1 HTN3
14 killing of cells of other organism GO:0031640 9.56 DEFA1 DEFB4A HTN3 LTF
15 defense response to protozoan GO:0042832 9.55 DEFA1 IRF8
16 response to molecule of bacterial origin GO:0002237 9.52 B2M CXCL8
17 membrane disruption in other organism GO:0051673 9.49 DEFA1 LTF
18 defense response to bacterium GO:0042742 9.43 DEFA1 DEFB1 DEFB4A HTN3 IRF8 LTF
19 antimicrobial humoral response GO:0019730 9.02 DEFA1 DEFB1 DEFB4A HTN3 LTF

Molecular functions related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Oral Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....